文献速递角膜与眼表疾病神经眼科青光眼

滴眼液防腐剂苯扎氯铵可强效诱导线粒体功能障碍并优先影响LHON突变细胞

The Eye Drop Preservative Benzalkonium Chloride Potently Induces Mitochondrial Dysfunction and Preferentially Affects LHON Mutant Cells.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

苯扎氯铵(BAK)是最常用的滴眼液防腐剂,但其眼部毒性机制不明。本研究测量人角膜上皮原代细胞(HCEP)及携带健康或Leber遗传性视神经病变(LHON)突变mtDNA的骨肉瘤杂交细胞在BAK急性处理前后的线粒体耗氧率,并检测BAK处理后的对照组、LHON突变组及人源性小梁网细胞(HTM3)的线粒体ATP合成与细胞活力。结果显示BAK通过直接靶向线粒体复合体I,以浓度依赖方式抑制线粒体ATP合成(IC50 5.3 μM)和耗氧(IC50 10.9 μM),在药用浓度(107–667 μM)下抑制线粒体功能>90%,对杂交细胞产生浓度依赖性细胞毒性(IC50 22.8 μM),并在相似浓度下诱导HTM3细胞凋亡;BAK在比滴眼液所用浓度低50倍的浓度下直接抑制HCEP细胞线粒体耗氧(IC50 3.8 μM),且携带LHON突变细胞对BAK的线粒体毒性更敏感。作者认为这可能是BAK眼部毒性的基础,并建议线粒体缺陷患者(包括LHON患者、LHON携带者及可能包括原发性开角型青光眼患者)避免使用含BAK滴眼液。

要点

  • BAK通过直接靶向线粒体复合体I,浓度依赖地抑制线粒体ATP合成(IC50 5.3 μM)和耗氧(IC50 10.9 μM)。
  • 在药用浓度107–667 μM下,BAK抑制线粒体功能>90%。
  • BAK在比滴眼液所用浓度低50倍的浓度下直接抑制HCEP细胞线粒体耗氧(IC50 3.8 μM)。

核心结论

  • BAK在药理学相关浓度下抑制人角膜上皮细胞和携带LHON突变细胞的线粒体,作者认为这是BAK眼部毒性的基础。
  • 作者建议线粒体缺陷患者(包括LHON患者、LHON携带者及可能包括原发性开角型青光眼患者)应避免使用含BAK滴眼液。

研究设计与样本

  • 测量人角膜上皮原代细胞(HCEP)及携带健康(对照)或LHON突变mtDNA[11778(G>A)]的骨肉瘤杂交细胞在BAK急性处理前后的线粒体耗氧率。
  • 检测BAK处理后的对照组、LHON突变组及人源性小梁网细胞(HTM3)的线粒体ATP合成与细胞活力。

主要发现

  • BAK以浓度依赖方式抑制线粒体ATP合成(IC50 5.3 μM)和耗氧(IC50 10.9 μM),直接靶向线粒体复合体I。
  • 在药用浓度107–667 μM下,BAK抑制线粒体功能>90%。
  • BAK对杂交细胞产生浓度依赖性细胞毒性(IC50 22.8 μM),并在相似浓度下诱导HTM3细胞凋亡。
  • BAK在比滴眼液所用浓度低50倍的浓度下直接抑制HCEP细胞线粒体耗氧(IC50 3.8 μM)。
  • 携带LHON突变的细胞对BAK的线粒体毒性进一步敏感。

关键数值与推荐

  • 线粒体ATP合成抑制的IC50为5.3 μM(BAK处理)。
  • 线粒体耗氧抑制的IC50为10.9 μM(BAK处理)。
  • BAK药用浓度为107–667 μM,在此浓度下抑制线粒体功能>90%。
  • 杂交细胞细胞毒性的IC50为22.8 μM(BAK处理)。
  • HCEP细胞线粒体耗氧抑制的IC50为3.8 μM(BAK处理),比滴眼液所用浓度低50倍。

临床怎么用

  • 作者建议线粒体缺陷患者(包括LHON患者、LHON携带者及可能包括原发性开角型青光眼患者)应避免使用含BAK滴眼液。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Benzalkonium chloride (BAK) is the most commonly used eye drop preservative. Benzalkonium chloride has been associated with toxic effects such as "dry eye" and trabecular meshwork degeneration, but the underlying biochemical mechanism of ocular toxicity by BAK is unclear. In this study, we propose a mechanistic basis for BAK's adverse effects. METHOD: Mitochondrial O2 consumption rates of human corneal epithelial primary cells (HCEP), osteosarcoma cybrid cells carrying healthy (control) or Leber hereditary optic neuropathy (LHON) mutant mtDNA [11778(G>A)], were measured before and after acute treatment with BAK. Mitochondrial adenosine triphosphate (ATP) synthesis and cell viability were also measured in the BAK-treated control: LHON mutant and human-derived trabecular meshwork cells (HTM3). RESULTS: Benzalkonium chloride inhibited mitochondrial ATP (IC50, 5.3 μM) and O2 consumption (IC50, 10.9 μM) in a concentration-dependent manner, by directly targeting mitochondrial complex I. At its pharmaceutical concentrations (107-667 μM), BAK inhibited mitochondrial function >90%. In addition, BAK elicited concentration-dependent cytotoxicity to cybrid cells (IC50, 22.8 μM) and induced apoptosis in HTM3 cells at similar concentrations. Furthermore, we show that BAK directly inhibits mitochondrial O2 consumption in HCEP cells (IC50, 3.8 μM) at 50-fold lower concentrations than used in eye drops, and that cells bearing mitochondrial blindness (LHON) mutations are further sensitized to BAK's mitotoxic effect. CONCLUSIONS: Benzalkonium chloride inhibits mitochondria of human corneal epithelial cells and cells bearing LHON mutations at pharmacologically relevant concentrations, and we suggest this is the basis of BAK's ocular toxicity. Prescribing BAK-containing eye drops should be avoided in patients with mitochondrial deficiency, including LHON patients, LHON carriers, and possibly primary open-angle glaucoma patients.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Datta S, Baudouin C, Brignole-Baudouin F, et al. The Eye Drop Preservative Benzalkonium Chloride Potently Induces Mitochondrial Dysfunction and Preferentially Affects LHON Mutant Cells. Invest Ophthalmol Vis Sci. 2017. PMID: 28444329. doi:10.1167/iovs.16-20903

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。